OSE Immuno

6.4700

13-March-25 04:57:01

15 minutes delayed

Stocks

-0.2600

-3.86%

Today's range

6.4500 - 6.5000

ISIN

FR0012127173

Source

Cboe

OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant

05 Jun 2024 01:30:00 By Nasdaq GlobeNewswire
OSE Immunotherapeutics Provides Business and Corporate Update

30 May 2024 12:15:00 By Nasdaq GlobeNewswire
OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases

22 May 2024 01:30:00 By Nasdaq GlobeNewswire
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective

16 Apr 2024 12:00:00 By Nasdaq GlobeNewswire
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer

10 Apr 2024 12:00:00 By Nasdaq GlobeNewswire
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology

02 Apr 2024 01:30:00 By Nasdaq GlobeNewswire
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update

27 Mar 2024 13:00:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.